HanchorBio Debuts on Taiwan Innovation Board with HCB101 Clinical Data Fueling Global Partnering Talks
Event summary
- HanchorBio to list on Taiwan Innovation Board at NT$120 per share on May 29, 2026.
- HCB101 shows 80% ORR in mid-dose gastric cancer cohort, supporting global partnering discussions.
- Company pursuing multi-indication strategy for HCB101 after $202M China licensing deal with Henlius.
- Pipeline includes HCB301 (Phase 1), HCB303 (planning), and HCB206 (autoimmune) programs.
The big picture
HanchorBio's listing comes as biotech investors increasingly value platform technologies capable of generating multiple clinical assets. The company's FBDB™ platform positions it in the competitive immuno-oncology space, where successful partnering could accelerate commercialization. The $202M Henlius deal sets a benchmark for future licensing discussions as HanchorBio expands HCB101's indication portfolio.
What we're watching
- Partnering Momentum
- Whether HCB101's Phase 2a data can secure additional global licensing deals beyond Henlius agreement.
- Pipeline Diversification
- How quickly HCB301 and HCB206 advance through clinical stages to reduce reliance on HCB101.
- Valuation Dynamics
- The pace at which market capitalization grows post-listing based on clinical milestones.
Related topics